These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37637207)

  • 1. Intratumoral injection of IL-12-encoding mRNA targeted to CSFR1 and PD-L1 exerts potent anti-tumor effects without substantial systemic exposure.
    Di Trani CA; Cirella A; Arrizabalaga L; Alvarez M; Bella Á; Fernandez-Sendin M; Russo-Cabrera JS; Gomar C; Ardaiz N; Teijeira A; Bolaños E; González-Gomariz J; Otano I; Aranda F; Palencia B; Segués A; Huang S; van Duijnhoven SMJ; van Elsas A; Melero I; Berraondo P
    Mol Ther Nucleic Acids; 2023 Sep; 33():599-616. PubMed ID: 37637207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists.
    Cirella A; Bolaños E; Luri-Rey C; Di Trani CA; Olivera I; Gomis G; Glez-Vaz J; Pinci B; Garasa S; Sánchez-Gregorio S; Azpilikueta A; Eguren-Santamaria I; Valencia K; Palencia B; Alvarez M; Ochoa MC; Teijeira Á; Berraondo P; Melero I
    Mol Ther Nucleic Acids; 2023 Sep; 33():668-682. PubMed ID: 37650116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo.
    Martomo SA; Patel J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1941-1950. PubMed ID: 36454338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.
    Fallon JK; Vandeveer AJ; Schlom J; Greiner JW
    Oncotarget; 2017 Mar; 8(13):20558-20571. PubMed ID: 28423552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
    Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
    Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
    [No Abstract]   [Full Text] [Related]  

  • 6. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvia mitiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade.
    Song M; Qian C; Zhang T; Tang Y; Zhou Y; Wei Z; Wang A; Zhong C; Zhao Y; Lu Y
    J Ethnopharmacol; 2023 Nov; 316():116735. PubMed ID: 37286115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
    Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
    Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy.
    Kim J; Kang S; Kim KW; Heo MG; Park DI; Lee JH; Lim NJ; Min DH; Won C
    Biomaterials; 2022 Jan; 280():121257. PubMed ID: 34839122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment.
    Hewitt SL; Bailey D; Zielinski J; Apte A; Musenge F; Karp R; Burke S; Garcon F; Mishra A; Gurumurthy S; Watkins A; Arnold K; Moynihan J; Clancy-Thompson E; Mulgrew K; Adjei G; Deschler K; Potz D; Moody G; Leinster DA; Novick S; Sulikowski M; Bagnall C; Martin P; Lapointe JM; Si H; Morehouse C; Sedic M; Wilkinson RW; Herbst R; Frederick JP; Luheshi N
    Clin Cancer Res; 2020 Dec; 26(23):6284-6298. PubMed ID: 32817076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
    Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using
    Liechtenstein T; Perez-Janices N; Blanco-Luquin I; Goyvaerts C; Schwarze J; Dufait I; Lanna A; Ridder M; Guerrero-Setas D; Breckpot K; Escors D
    Oncoimmunology; 2014; 3(7):e945378. PubMed ID: 25954597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Dose Anti-PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses.
    Martomo SA; Lu D; Polonskaya Z; Luna X; Zhang Z; Feldstein S; Lumban-Tobing R; Almstead DK; Miyara F; Patel J
    Mol Cancer Ther; 2021 Feb; 20(2):347-356. PubMed ID: 33293344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.